China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class ASZSE: 300294

China Resources Boya Bio-pharmaceutical Group: Revenue up, profit down sharply on impairments and margin pressure; high dividend payout maintained

· Issued by China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

Revenue grew 18.7% year-over-year, but net profit fell 71.6% due to asset impairments and lower margins amid industry headwinds. The company divested a loss-making subsidiary, advanced new product launches, and maintained a high dividend payout.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

All China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A news releases